ArticleEuropean radiology2025
Radiomics-driven spectral profiling of six kidney stone types with monoenergetic CT reconstructions in photon-counting CT.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Photon-counting CT-enabled urolithiasis phenotyping: virtual non-iodine reconstructions, automated measurement, and spectral radiomics.Abdominal radiology (New York) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUrolithiasis, a common and painful urological condition, is influenced by factors such as lifestyle, genetics, and medication. Differentiating between different types of kidney stones is crucial for personalized therapy. The purpose of this study is to investigate the use of photon-counting computed tomography (PCCT) in combination with radiomics and machine learning to develop a method for automated and detailed characterization of kidney stones. This approach aims to enhance the accuracy and detail of stone classification beyond what is achievable with conventional computed tomography (CT) and dual-energy CT (DECT). MATERIALS AND
methodsIn this ex vivo study, 135 kidney stones were first classified using infrared spectroscopy. All stones were then scanned in a PCCT embedded in a phantom. Various monoenergetic reconstructions were generated, and radiomics features were extracted. Statistical analysis was performed using Random Forest (RF) classifiers for both individual reconstructions and a combined model.
resultsThe combined model, using radiomics features from all monoenergetic reconstructions, significantly outperformed individual reconstructions and SPP parameters, with an AUC of 0.95 and test accuracy of 0.81 for differentiating all six stone types. Feature importance analysis identified key parameters, including NGTDM_Strength and wavelet-LLH_firstorder_Variance.
conclusionThis ex vivo study demonstrates that radiomics-driven PCCT analysis can improve differentiation between kidney stone subtypes. The combined model outperformed individual monoenergetic levels, highlighting the potential of spectral profiling in PCCT to optimize treatment through image-based strategies. KEY POINTS: Question How can photon-counting computed tomography (PCCT) combined with radiomics improve the differentiation of kidney stone types beyond conventional CT and dual-energy CT, enhancing personalized therapy? Findings Our ex vivo study demonstrates that a combined spectral-driven radiomics model achieved 95% AUC and 81% test accuracy in differentiating six kidney stone types. Clinical relevance Implementing PCCT-based spectral-driven radiomics allows for precise non-invasive differentiation of kidney stone types, leading to improved diagnostic accuracy and more personalized, effective treatment strategies, potentially reducing the need for invasive procedures and recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.